Phase II Trial of low-dose Sandimmun Optoral (Cyclosporine A) for the treatment of primary Sjogren's syndrome (pSS)

Trial Profile

Phase II Trial of low-dose Sandimmun Optoral (Cyclosporine A) for the treatment of primary Sjogren's syndrome (pSS)

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Sjogren's syndrome
  • Focus Therapeutic Use
  • Acronyms CYPRESS
  • Most Recent Events

    • 28 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Sep 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01693393).
    • 25 Sep 2012 Planned end date 1 Mar 2014 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top